Limeng Wu

Peking Union Medical College Hospital, Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain.

Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: August 23, 2025

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation.

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation.

Journal: Theranostics

Published: August 14, 2025

A Comparison of the Effect of Remimazolam and Midazolam on Recovery and Preserved Memory Function for Patients with Dental Extraction Anxiety.

A Comparison of the Effect of Remimazolam and Midazolam on Recovery and Preserved Memory Function for Patients with Dental Extraction Anxiety.

Journal: Drug design, development and therapy

Published: July 04, 2025

NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.

NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.

Journal: Nature communications

Published: March 04, 2025

Risk Factors for Venous Thromboembolism Following Oral and Maxillofacial Cancer Surgery With Free Flap Reconstruction.

Risk Factors for Venous Thromboembolism Following Oral and Maxillofacial Cancer Surgery With Free Flap Reconstruction.

Journal: Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons

Published: January 15, 2025

Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.

Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.

Journal: bioRxiv : the preprint server for biology

Published: January 07, 2025

Impact of preoperative comorbidities on postoperative complication rates and survival outcome in patients with head and neck cancer undergoing surgical treatment.

Impact of preoperative comorbidities on postoperative complication rates and survival outcome in patients with head and neck cancer undergoing surgical treatment.

Journal: Scientific reports

Published: September 23, 2024

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.

Journal: Cancers

Published: April 23, 2024

Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.

Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.

Journal: British journal of cancer

Published: February 05, 2024

Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain.

Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain.

Journal: bioRxiv : the preprint server for biology

Published: February 17, 2023

Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.

Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.

Journal: PloS one

Published: January 15, 2022

Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.

Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.

Journal: Science translational medicine

Published: June 23, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026